Prospects for a nonliving vaccine against schistosomiasis based on cell-mediated immune resistance mechanisms.
We have designed a vaccine model based on induction of cell-mediated immunity and shown that it protects mice against Schistosoma mansoni infection. Mice are immunized by intradermal injection with schistosome antigens plus BCG. Resistance is dependent on the route of antigen presentation and the adjuvant chosen. The pattern of resistance correlates with sensitization of T lymphocytes for production of gamma interferon, a macrophage activating lymphokine that stimulates the cellular effector mechanism of protection. Purified schistosome paramyosin, a muscle cell component present in soluble parasite antigenic preparations, is immunogenic for T lymphocytes and induces resistance when given intradermally with BCG. It is likely that this protein, and possibly other soluble molecules that are released by the parasites of a challenge infection, induce a cellular inflammatory response resulting in larval trapping and/or killing by activated macrophages. These results verify the feasibility of a vaccine against schistosomiasis based on induction of cell-mediated immune resistance mechanisms.
James
S L
SL
Department of Medicine, George Washington University Medical Center, Washington, D.C. 20037.
Pearce
E J
EJ
Sher
A
A
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000947:Antigens, Helminth / Q000008:administration & dosage / Q000276:immunology*; D001500:BCG Vaccine / Q000008:administration & dosage; D007111:Immunity, Cellular; D007114:Immunization / Q000379:methods; D007271:Injections, Intradermal; D008262:Macrophage Activation; D051379:Mice; D012550:Schistosoma mansoni / Q000276:immunology*; D012555:Schistosomiasis mansoni / Q000517:prevention & control*; D013601:T-Lymphocytes / Q000276:immunology; D014612:Vaccines / Q000276:immunology* / Q000302:isolation & purification
D000276:Adjuvants, Immunologic; D000947:Antigens, Helminth; D001500:BCG Vaccine; D014612:Vaccines